LISTEN: While not a replacement for the measles vaccine, an oral antiviral developed at Georgia State University could be an option for more vaccine-hesitant populations. GPB's Sofi Gratas explains.

A pair of gloved hands hold a syringe and the MMR vaccine

Caption

False claims about vaccines such as the measles/mumps/rubella vaccine (above) have led to growing public mistrust in the disease-preventing measure.

Credit: Adobe Stock

The data is clear: Far fewer people, specifically children, are getting vaccinated against infectious diseases now than in the past. 

False claims about vaccines have led to growing public mistrust. And when these claims are amplified by public health officials, there are measurable results. 

Researchers out of Georgia State University are considering additional ways to prevent disease spread, by testing out an antiviral against measles-like diseases. 

To effectively test a potential antiviral treatment for measles, there would need to be clinical trials on humans. Microbiologist Richard Plemper and his team at Georgia State have instead tested on a cousin of the measles virus: canine distemper. 

The research, published in the science magazine Nature Microbiology, is funded by the National Institutes of Health.

“We want to be able to have a drug that people can take at home — make the hurdle as low as possible,” Plemper said.

They tested the oral antiviral pre- and post-exposure to the virus on ferrets. The key was to look at not whether the animals were exposed to the virus, which is inevitable, but if their immune systems recognized the pathogen and responded. 

In the pre-clinical trials, Plemper’s team found little to no detectable antibodies in the animals' immune systems. 

"We can completely prevent any disease in the contacts," Plemper said. "So complete success."

If an antiviral were developed for human measles, it would not be a replacement for the measles vaccine, which is the most effective way to prevent disease. But Plemper says it could be a good option for people who are vaccine-hesitant, especially as the U.S. is on track to lose its measles elimination status. 

"Where we are now, we feel there is a need to augment vaccination, but with a pharmacological option," Plemper said. 

Uptake would still ultimately be up to the public. 

This fall, the Pan American Health Organization will review epidemiological evidence on measles outbreaks in the U.S. and decide whether the country has retained or lost its elimination status, held since 2000. 

There were more cases of measles this year — case counts currently stand at 2,465 — than in any other year in the past two decades. 

Georgia has largely been spared, with only five reported measles cases this year so far. That’s still double last year’s case count. 

Support Local Journalism

GPB believes that everyone should have access to trustworthy, fact-based stories that connect them to their community and outward to the wider world. Your donation will help us in our efforts to unite and uplift Georgia.

GPB is vital. Always educational, essential, inspiring and grounding. So happy to be a supporter.

— Kelli D., Athens, Ga.